Off-the-shelf allogeneic NK cells engineered with a CAR targeting glypican-3 (GPC3) recognize GPC3-expressing tumor cells and trigger NK-mediated cytotoxicity (perforin/granzyme and cytokine release). The product includes calibrated-release IL-15 to enhance NK-cell survival, proliferation, and persistence in vivo.